Miruvor
Sign up
The short answer

What studies of NAC (N-acetylcysteine) found

19papers on NAC (N-acetylcysteine)
20people in 1 study testing NAC (N-acetylcysteine) alone
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: NAC (N-acetylcysteine) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 19 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. NAC (N-acetylcysteine) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue1 study · 20 people took NAC (N-acetylcysteine) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (20 in all); not all results were tested against chance.

Studies with no comparison group20 in the study · eine Woche lang · 600 mg, einmal täglich Off-Label

Fatigue improved.

The evidence is very uncertain about the effect of NAC (N-acetylcysteine) on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (20 in all)
  • Not all results were tested against chance
See the 1 study
  1. Retrospektive Analyse der NAC-Therapie bei Post-Covid Syndrom (2024)

    People in the study
    20 in the study
    Dose
    600 mg, einmal täglich Off-Label
    Outcome
    FAS-Score Fatigue Assessment Scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Daily functioning1 study · 20 people took NAC (N-acetylcysteine) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (20 in all); not all results were tested against chance.

Studies with no comparison group20 in the study · eine Woche lang · 600 mg, einmal täglich Off-Label

Daily functioning improved.

The evidence is very uncertain about the effect of NAC (N-acetylcysteine) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (20 in all)
  • Not all results were tested against chance
See the 1 study
  1. Retrospektive Analyse der NAC-Therapie bei Post-Covid Syndrom (2024)

    People in the study
    20 in the study
    Dose
    600 mg, einmal täglich Off-Label
    Outcome
    klinisch signifikante Verbesserung ihrer funktionellen Beeinträchtigung Fatigue Assessment Scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Studies of combinations

Outcomes that only studies of NAC (N-acetylcysteine) given together with other treatments looked at. Shown, not graded: they can’t tell what NAC (N-acetylcysteine) did alone.

Overall symptoms ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): CGI-I, better.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Combination: Glutamine + NAC (N-acetylcysteine) + Zinc + Leaky gut protocol and supplements + L-carnitine + CoQ10 / ubiquinol + Taurine + Alpha-lipoic acid (ALA, R-ALA) + Turmeric / curcumin + Baicalein and quercetin41 in the study

Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. (2008): Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF scale), better (not tested).

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Fatigue ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): Chalder Fatigue Scale (CFQ), better.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Cognition (brain fog) ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): memory, item 11, and problems starting things, item 4, no clear difference.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Combination: Levothyroxine (Synthroid) + Natural desiccated thyroid (Armour, NP Thyroid) + Doxycycline (Vibramycin) + Nystatin + a different antibiotic + Succinic acid + NAC (N-acetylcysteine) + Bromelain + a liver detox blend + Antibiotics (unspecified) + Gentamicin + Hydroxychloroquine / Plaquenil + Dipyridamole (Persantine) + Lactoferrin and colostrum + Astragalus + Andrographis + AHCC and medicinal mushrooms (reishi, shiitake, maitake) + Fluconazole (Diflucan) + Kelp + Ashwagandha + Eleuthero (Siberian ginseng) + Licorice and glycyrrhizin + Fludrocortisone / Florinef + Trauma work (EFT, EMDR, TRE) + light therapy + Inosine + PABA (para-aminobenzoic acid) + DMAE + Lyme / co-infection protocols + Colloidal silver + Olive leaf extract + Antimicrobial botanicals (other) + Neem1 in the study

Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present. (2021): doing better cognitively, better (not tested).

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Depression ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): total MADRS score, no clear difference.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Sleep ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): ISI, better.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Daily functioning ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): WSAS, no clear difference.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Combination: Levothyroxine (Synthroid) + Natural desiccated thyroid (Armour, NP Thyroid) + Doxycycline (Vibramycin) + Nystatin + a different antibiotic + Succinic acid + NAC (N-acetylcysteine) + Bromelain + a liver detox blend + Antibiotics (unspecified) + Gentamicin + Hydroxychloroquine / Plaquenil + Dipyridamole (Persantine) + Lactoferrin and colostrum + Astragalus + Andrographis + AHCC and medicinal mushrooms (reishi, shiitake, maitake) + Fluconazole (Diflucan) + Kelp + Ashwagandha + Eleuthero (Siberian ginseng) + Licorice and glycyrrhizin + Fludrocortisone / Florinef + Trauma work (EFT, EMDR, TRE) + light therapy + Inosine + PABA (para-aminobenzoic acid) + DMAE + Lyme / co-infection protocols + Colloidal silver + Olive leaf extract + Antimicrobial botanicals (other) + Neem1 in the study

Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present. (2021): return to graduate school, better (not tested).

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Quality of life ME/CFS

Combination: CoQ10 / ubiquinol + Alpha-lipoic acid (ALA, R-ALA) + NAC (N-acetylcysteine) + L-carnitine + Magnesium + Vitamin C + Vitamin D and sun exposure + Vitamin E (tocopherol, tocotrienols) + Vitamin A (retinol) + Biotin + Thiamine / benfotiamine + Riboflavin (vitamin B2) + Niacinamide (nicotinamide) + Pantothenic acid (vitamin B5) + Vitamin B6 (pyridoxine, P5P) + Folate / folic acid supplements + Vitamin B1210 in the study

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study (2017): individual measures of the SF-12, no clear difference.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Overall symptoms Preventing long COVID

Combination: NAC (N-acetylcysteine) + Spirulina (Energy Bits)66 randomised

Therapeutic Efficacy of Spirulina Algae and N-Acetylcysteine in COVID-19 Hospitalized Patients: A Randomized Phase II Clinical Trial (2024): frequency of symptoms after discharge in the three-month follow-up, no clear difference.

Shown, not counted: NAC (N-acetylcysteine) was given together with other treatments.

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    600 to 900 mg at the start in most studies

  2. 2Raise

    Raised step by step in 1 of 5 studies

  3. 3Top dose

    Most often 600 mg (2 of 5 studies)

All papers

  1. N-acetylcysteine (NAC) supplementation improves dyspnea and may normalize von Willebrand plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.2025 · compared with another group · 9 in the study
    Summary

    This retrospective chart review examined 9 gynecologic patients with PASC/LC followed in a Gynecologic Oncology clinic. Three patients reported regular oral NAC supplementation (600–1200 mg BID) at different times after PASC/LC diagnosis; 6 randomly selected patients with PASC/LC symptoms who did not use the supplement served as controls. The study period was described as over the 4-year study period. The authors evaluated subjective symptoms—shortness of breath at rest and/or while walking, brain fog, and fatigue—and plasma von Willebrand factor (vWF) levels. Patients using NAC supplementation experienced subjective improvement in shortness of breath, brain fog, and fatigue. Subjective improvement in shortness of breath, brain fog, and fatigue with normalization of vWF levels was noted in 3 out of 3 PASC/LC patients using oral NAC versus none of the randomly selected control patients with PASC/LC (Fisher’s exact P = 0.0119). The authors also reported subjective improvement in performance status and decrease/normalization of vWF levels even in PASC/LC patients symptomatic for years. Harms and withdrawals were not reported. The authors state that no specific symptoms questionnaire was available for this retrospective review and refer to their small series.

  2. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  3. Retrospektive Analyse der NAC-Therapie bei Post-Covid Syndrom2024 · no comparison group · 20 in the study
  4. Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
    Summary

    This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.

  5. Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review.2023 · case report
    Summary

    This case report with a brief literature review describes Patient-X and Patient-Y, from the same home, with long COVID/PASC. Patient-X took Nitazoxanide 500 mg three times daily for 6 days; Patient-Y took Acyclovir 800 mg 5 times daily for 7 days. There was no comparison group; the report describes symptoms before and after treatment. Other medications did not help Patient-X: Metronidazole, antibiotics, Naproxen, and further medications tried for ~2 weeks. After the Nitazoxanide course, Patient-X noticed a remarkable improvement; in ~3 days the blocked nostril opened and swollen tonsil normalized, with congestion and cough cleared after ~14 months of symptoms. The rest of her problems disappeared soon, and she resumed normal life including exercising without relapse. After Acyclovir, Patient-Y felt significantly better and all symptoms disappeared shortly after ~12 months. Side effects were not reported. The authors state limitations: no COVID-19 testing at the beginning of the pandemic and no sequencing to differentiate persistence versus reinfection.

  6. Case Report: Mitochondrial insufficiency underlies cholinergic failure in post-vaccination long COVID: a candidate treatment protocol.2026 · combination: given with other treatments · 1 in the study
    Summary

    This single self-case report described an 80-year-old male professor with severe post-vaccination long COVID. Mestinon (pyridostigmine bromide) 90 mg daily had provided minimal benefit over 2 months. A comprehensive mitochondrial support protocol was then started: nicotinamide riboside 500 mg daily, ubiquinol one gram daily, high-dose B-complex vitamins, zinc 30 mg daily, copper two mg daily, creatine monohydrate five grams daily, N-acetylcysteine 900 mg daily, vitamin B12 as two chewable tablets daily plus intramuscular injections twice monthly, continued Mestinon 90 mg daily, continued nortriptyline 20 mg daily, all with seven ounces of fresh-squeezed orange juice three times daily. There was no comparison group, blinding or randomization. Clinical response was reported as dramatic within 48 h, with sustained functional recovery over 6 weeks. The report describes symptom recurrence within 4–6 h after missed morning doses on two occasions, resolution within 1–2 h after the delayed dose, minimal benefit with intentional reversal of component sequence for 5 days, complete loss of symptom control and being bedridden when water was substituted for orange juice, and noticeable improvement within 30 min, ability to walk one-eighth mile at 45 min, and complete functional recovery within 1–2 h after the evening dose with orange juice. Validated patient-reported outcome instruments were not administered. The authors state limitations including no blinding or randomization and possible placebo/nocebo effects.

  7. Therapeutic Efficacy of Spirulina Algae and N-Acetylcysteine in COVID-19 Hospitalized Patients: A Randomized Phase II Clinical Trial2024 · combination: given with other treatments · 66 randomised
    Summary

    The study aimed to evaluate spirulina and N-acetylcysteine in the treatment of hospitalized patients with Coronavirus Disease 2019 (COVID-19). This multicenter, randomized, single-masked, open-label phase II clinical trial enrolled 66 patients with COVID-19. Patients were randomly assigned to one group that received spirulina algae (23 people), one group that received N-acetylcysteine plus spirulina algae (21 people), or a control group (22 people) that received only the national standard treatment for COVID-19. The intervention groups were prescribed 80 mg/kg of spirulina green algae daily; the N-acetylcysteine dose and treatment duration were not reported. The study reported no significant difference between the three groups for duration of hospitalization (P = 0.874), Intensive Care Unit (ICU) admission (P = 0.320), or mortality (P = 0.320). Side effects, including headache (P = 0.022) and nausea (P = 0.039), were significantly less common in the control group. At the three-month follow-up, no statistically significant difference was observed regarding the frequency of symptoms after discharge (P = 0.420). The authors concluded that administering spirulina with or without N-acetylcysteine did not affect length of hospitalization, ICU admission, mortality, and the frequency of symptoms or long COVID. The text does not report limitations.

  8. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”2022 · combination: given with other treatments · 12 in the study
    Summary

    This case report series followed 12 patients with long-COVID cognitive complaints (“brain fog”) who were prescribed extended-release guanfacine and NAC. Guanfacine was started at 1 mg PO at night for the first month and often increased to 2 mg after 1 month if well-tolerated; NAC was given as 600 mg daily. Treatment duration and follow-up were not reported. There was no comparison group; the report describes an open-label clinical experience. Cognitive abilities improved in eight of the twelve patients. Those who stayed on guanfacine+NAC reported improved working memory, concentration, and executive functions, including resumption of normal workloads; some reported that brain fog decreased or went away completely, one reported less difficulty with word-finding, and two described feeling more like themselves. One nurse reported benefits in working memory, executive functioning and cognitive processing speed, return to a normal caseload, and rated guanfacine the “most effective medication” she had been on. One patient briefly stopped guanfacine due to a hypotensive episode and reported return of cognitive deficits that abated with resumed guanfacine. Four patients discontinued therapy, two for unspecified reasons and two due to hypotension and/or dizziness. The authors call for placebo-controlled trials.

  9. Chronic Fatigue Syndrome: A Case Report Highlighting Diagnosing and Treatment Challenges and the Possibility of Jarisch-Herxheimer Reactions If High Infectious Loads Are Present.2021 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one patient with severe ME/CFS who presented to a rheumatologist’s office in August 2013 after becoming bedridden 4.5 years earlier. Over a 4-year period from September 2013 to August 2017, the patient received a changing protocol that included thyroid medications, antibiotics, antifungals, Hydroxychloroquine, colostrum, kelp, licorice root, fludrocortisone, EFT, EMDR, light therapy, and multiple herbs and supplements. No comparison group was reported. The report described function and symptoms over time. By the Spring of 2014 (~6 months after onset of treatment), she had improved enough to take a college course 1 day/week but was not well enough to drive. By February 2015 she was still predominantly housebound; she was doing better cognitively, but simple activity like walking was still too difficult on most days. She was back at the gym by April 2017 and going for walks daily. In August 2017 she was well enough to move out from her parents’ home and resume graduate school, and she had been stable for at least 6 months. Reported harms included Jarisch–Herxheimer reactions with severe joint and musculoskeletal pain, worsening fatigue, worsening cognitive function, migraines, and drops in blood pressure; doxycycline was discontinued. She also had severe reactions from all supplements, severe discomfort during EFT/EMDR sessions, and could not tolerate blue light more than 1–2 min without severe migraines. The authors stated it was not possible to determine whether improvements were mediated by treatments or spontaneous remission/placebo.

  10. Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study2017 · combination: given with other treatments · 10 in the study
    Summary

    This 16-week open-label pilot study examined a combination nutraceutical of mitochondrial agents in 10 patients with chronic fatigue syndrome recruited through clinicians and based at The Melbourne Clinic in Melbourne, Australia. Participants received twice-daily dosing of Co Q10, alpha lipoic acid, N-acetylcysteine, Acetyl L-carnitine, B vitamins and co-factors for 16 weeks, with no placebo comparison. Assessments occurred at baseline, W4, W8, W12 and W16 and included the Chalder Fatigue Scale (CFQ), MADRS, ISI, PGI, CGI-S, CGI-I, WSAS and SF-12. Mean total CFQ scores fell from 22.0 (6.07) at baseline to 12.6 (7.46) at Week 16 (F(4,29) = 6.31, p < 0.001); the baseline-to-Week 4 mean difference was 7.66 (p < 0.01). Nine of 11 CFQ items showed significant improvement, while memory (item 11) and problems starting things (item 4) did not. ISI (p = 0.017) and CGI-I (p = 0.014) improved; MADRS (p = 0.225), PGI (p = 0.33), CGI-S (p = 0.150), WSAS (p = 0.095) and SF-12 measures did not change significantly. Adverse events included headaches/migraines (n = 3), minor gastritis (n = 4), loss of appetite/feeling of fullness (n = 1), brief tachycardia (n = 1) and skin pigmentation on the forehead (n = 1); no serious adverse events were noted, and no participants withdrew due to adverse events. Two participants (20%) withdrew before termination, at week four and week twelve, due to work commitments.

  11. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · combination: given with other treatments · 76 in the study
    Summary

    Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.

  12. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria.2008 · combination: given with other treatments · 41 in the study
    Summary

    This non-interventional study asked whether gut-derived LPS translocation and clinical severity change in chronic fatigue syndrome. Forty-one patients were consecutively admitted to the M-Care4U Outpatient Clinics, Belgium, and selected for initial increases in IgM and/or IgA responses to LPS. All followed a leaky gut diet and took glutamine, zinc and NAC, plus other NAIOSs (L-carnitine, coenzyme Q10, taurine, lipoic acid, curcumine, quercitine) for 10-12 months (also reported as 10-14 months). There was no comparison group; before and endpoint measures were compared. Outcomes included the Fibromyalgia and Chronic Fatigue Syndrome Rating Scale (FF scale) and IgM/IgA responses to LPS. The mean FF score was 38.8 at baseline and 14.0 at endpoint. Overall, 26 (63.5%) patients showed a good clinical response, while 15 (36.5%) showed less clinical improvement. At endpoint, responders had FF 7.7 versus non-responders 24.9; patients ill <5 years had 7.3 versus >5 years 18.7; age <38 years had 10.6 versus >38 years 17.6. The overall age comparison was not significant (p=0.2). Side effects and withdrawals were not reported.

  13. Traditional, complementary and integrative medicine for fatigue post COVID-19 infection: A systematic review of randomized controlled trials.2024 · systematic review
    Summary

    This systematic review asked whether traditional, complementary and integrative medicine reduces fatigue after COVID-19. It included thirteen RCTs with 1632 participants; participants from eight RCTs were conducted in China. Searches ran to 12 April 2023. Trials compared herbal and Chinese medicine, probiotics/systemic enzymes, aromatherapy, neuro-meditation, progressive muscle relaxation, and other approaches with placebo, no treatment, or rehabilitation/conventional comparators. For Ludangshen oral liquid versus placebo, fatigue severity was MD -1.90 [-2.38, -1.42], P<0.001; fatigue disappearance RR 4.19 [2.06, 8.53], P<0.001; remission RR 2.04 [1.58, 2.63], P<0.001. Bufei Huoxue capsules versus placebo had MD -14.90 [-24.53, -5.27], P=0.02; Qingjin Yiqi granules plus TCM rehabilitation versus TCM rehabilitation had MD -0.48 [-0.50, -0.46], P<0.001. ADAPT-232/Chisan® versus placebo had MD -1.02 [-2.40, 0.36], P=0.15. Adverse events included abnormal liver function 4 with Bufei Huoxue and 2 with placebo; liver injury 1; diarrhea 1; excessive menstruation 1. None of the trials reported serious adverse events.

  14. The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
    Summary

    This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.

  15. Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities.2026 · review
    Summary

    This narrative review used pragmatic methods and searches up to January 2025 to map candidate treatments for long COVID that clinicians and people with lived experience prioritised. No participant total for the review itself was reported. Evidence was summarised across intervention groups. A moderate-quality RCT of 155 participants found no significant improvement with Paxlovid. In a non-randomised controlled trial of fexofenadine plus famotidine, 14 patients were in the treatment group and 13 in the control group; 29% of treated patients had complete resolution of long COVID symptoms, and all treated patients showed significant improvement in fatigue, brain fog, abdominal disorders, and increased heart rate compared with controls. A single case report found eight out of 12 reported improved cognitive abilities with guanfacine plus N-acetylcysteine; four patients discontinued therapy, two for unspecified reasons and two due to hypotension and/or dizziness. A pilot RCT of 13 participants found active taVNS (n = 8) improved fatigue, mood, and cognitive symptoms compared with sham (n = 5), with no serious adverse events observed. A small RCT found no significant differences with 700 mg leronlimab. Two RCTs did not report any benefit from CoQ10. A case study of 4 participants reported symptom improvements up to 6 months after nicotine patches 7.5 mg per day for 7 days. Five RCTs reported multicomponent interventions improved quality of life and dyspnoea, with no strong evidence for other symptoms; 16 RCTs examined exercise training.

  16. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  17. Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine.2025 · review
    Summary

    This narrative review aimed to summarise evidence on the potential therapeutic role of N-acetylcysteine (NAC) and acetyl-L-carnitine (ALC) in neuropsychiatric manifestations of COVID-19 and Post COVID Syndrome, and to propose a pathophysiological model. It covers acute COVID-19, ongoing symptomatic COVID-19, PCS, and overlap with CFS. The setting is not reported. No patients enrolled, started, or analysed are reported, and no comparison group, randomisation, crossover, or follow-up is reported. The review did not administer a treatment or report a treatment duration. It discusses NAC and ALC mechanisms and cites a randomised study by Scaturro et al. in which ALC was used for depressive symptoms associated with Long COVID; patient numbers are not reported. The review reports no own results, no between-group results, no harms, no withdrawals, and no side-effect counts. Its conclusions state that NAC reduces KYNA levels, potentially ameliorating COVID-related cognitive dysfunction; that ALC was found effective in treating depressive symptomatology of PCS; that ALC and NAC could ameliorate fatigue through different mechanisms, including combined glutamatergic action; and that NAC and ALC hold promise for neuropsychiatric conditions associated with COVID-19 and PCS. The authors state that the speculative nature of their inferences must be considered.

  18. Beyond Antivirals: Alternative Therapies for Long COVID.2024 · review
    Summary

    This scoping review searched PubMed from January 2021 to September 2024 and included 18 studies of non-antiviral treatments for Long COVID/PASC. The review itself had no comparison group and was not randomized; the included evidence came from randomized trials, observational research, and case series. Treatment duration was not reported. Reported findings included metformin in two phase 3 trials with reductions in Long COVID incidence of 42% to 63%; LDN with over 50% of participants reporting cognitive improvements and a five-fold higher likelihood of improvement compared with physical therapy alone; dexamethasone with a 33% reduction in fatigue and median symptom duration of 133 days vs. 271 days; omega-3 fatty acids in 33,908 patients with moderate improvements in mental health and musculoskeletal symptoms; L-arginine plus vitamin C with 94.9% reporting absence of fatigue and 74.2% no dyspnea; therapeutic apheresis with significant improvements in 70% of 27 patients; and IVIg with improved fatigue and cognitive dysfunction in 70–75% of patients. NAC improved cognitive function in 67% of 12 patients but had a 25% discontinuation rate due to side effects; a small percentage discontinued LDN due to mild side effects such as fatigue and gastrointestinal symptoms. The authors state limitations including heterogeneity, observational or small-scale evidence, and limited long-term data.

  19. Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities.2019 · review
    Summary

    This review asks why pathophysiological insights in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) might point to treatments, and it examines treatment data for antioxidant and anti-inflammatory options. It reports no primary enrolment or analysis; it discusses patients diagnosed with ME/CFS by international consensus or Fukuda criteria and reviews CBT, GET, curcumin, NAC, CoQ10, melatonin, probiotics/prebiotics and molecular hydrogen. For the PACE trial, it reports that a year of CBT produced modest and short-term reductions in fatigue of some 10% compared with an untreated control group and a non-significant worsening of distance walked in six minutes. It also reports that CBT and GET reduced self-reported fatigue by some 13% compared with no treatment after 52 weeks, that GET improved six-minute walking distance by 31m compared with no treatment, and that GET for 12 months was associated with a 67m improvement versus 22m with specialist medical care alone. In 60 patients selected by international consensus criteria, graded exercise over a 12-month period was reported to worsen physical function and pain. Hydrogen-rich water studies in Parkinson’s disease (1,000 mL/day over a 48-week period) and rheumatoid arthritis (500 mL of 1 ppm for four weeks) reported improvements versus controls. The authors state these data are promising yet preliminary.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime